Last edition
News about "Phase 3 clinical trials"
EMA Backs Marketing Authorisation for Janssen's Icotyde in Plaque Psoriasis
CHMP backs marketing authorisation for icotrokinra to treat moderate-to-severe plaque psoriasis in adults and eligible adolescents, potentially making it the first oral IL-23-targeting therapy approved in the EU.
Phase 3 Clinical Trials | 27/07/2026 | By News Bureau
European Commission Approves Dupixent for Young Children with Chronic Spontaneous Urticaria
The European Commission has expanded approval of Dupixent to children aged 2–11 with chronic spontaneous urticaria, offering a targeted treatment for those unresponsive to standard antihistamines.
Phase 3 Clinical Trials | 15/04/2026 | By News Bureau | 142
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy